NRT Share Price

Open 0.05 Change Price %
High 0.05 1 Day 0.00 0.00
Low 0.05 1 Week 0.00 0.00
Close 0.05 1 Month 0.00 0.00
Volume 365628 1 Year -0.05 -50.00
52 Week High 0.12
52 Week Low 0.04
NRT Important Levels
Resistance 2 0.05
Resistance 1 0.05
Pivot 0.05
Support 1 0.05
Support 2 0.05
ASX Australia Most Active Stocks
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TLS 4.32 -0.23%
TLS 4.32 -0.23%
TLS 4.32 -0.23%
DJS 3.99 0.00%
DJS 3.99 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
GBP 0.04 100.00%
GBP 0.04 100.00%
POH 0.02 100.00%
BNV 0.03 50.00%
PVE 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
AHN 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
ANO 0.02 -33.33%
ANO 0.02 -33.33%
ANO 0.02 -33.33%
ICN 0.02 -33.33%
More..

Novogen Ltd (ASX: NRT)

NRT Technical Analysis 4
As on 22nd Jun 2017 NRT Share Price closed @ 0.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.08 & Sell for SHORT-TERM with Stoploss of 0.05 we also expect STOCK to react on Following IMPORTANT LEVELS.
NRT Target for June
1st Target up-side 0.06
2nd Target up-side 0.07
3rd Target up-side 0.08
1st Target down-side 0.04
2nd Target down-side 0.03
3rd Target down-side 0.02
NRT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.novogen.com
NRT Address
NRT
16 - 20 Edgeworth David Avenue
Level 1
Hornsby, NSW 2077
Australia
Phone: 61 2 9476 0344
Fax: 61 2 9476 0388
NRT Latest News
Interactive Technical Analysis Chart Novogen Ltd ( NRT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novogen Ltd
NRT Business Profile
Novogen Limited operates as a pharmaceutical drug development company worldwide. It focuses on the development of a family of anti-cancer drugs based on super-benzopyran and stealth drug technologies. The company’s lead drug candidate is CS-6, a mitochondrial electron transfer inhibitor for the treatment of temozolomide-resistant glioblastoma multiforme and late-stage chemo-refractory ovarian cancer. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.